Dilantin-induced disseminated intravascular coagulation with purpura fulminans. A case report.
A patient developed disseminated intravascular coagulation with purpura fulminans 1 month after starting Dilantin therapy for a seizure disorder. In addition, the patient developed exfoliative dermatitis, hepatitis, cutaneous vasculitis, and microangiopathic hemolytic anemia. She was successfully treated with adrenal steroids and heparin for her purpura fulminans. The hepatitic dermatologic, along with hemorrhagic, complications of Dilantin are reviewed, and the possible origin of the vasculitis and disseminated intravascular coagulation is discussed.
D000293:Adolescent; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced*; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D011693:Purpura / Q000139:chemically induced* / Q000188:drug therapy; D012867:Skin / Q000473:pathology
D010672:Phenytoin; D006493:Heparin; D008775:Methylprednisolone